A phase 2 randomised study to establish efficacy, safety and dosing of a novel oral cathepsin C inhibitor, BI 1291583, in adults with bronchiectasis: Airleaf 由 Chalmers, James D., Gupta, Abhya, Chotirmall, Sanjay Haresh, Armstrong, April, Eickholz, Peter, Hasegawa, Naoki, McShane, Pamela J., O'Donnell, Anne E., Shteinberg, Michal, Watz, Henrik, Eleftheraki, Anastasia, Diefenbach, Claudia, Sauter, Wiebke

获取全文